Results for T-ALL

Share:
1 - 10 of 11

CART38, a Novel Therapy for T-ALL: Q&A With David Teachey, MD, and Caroline Diorio, MD

Published on
Jan 19, 2023
in Cornerstone Blog
Seed Grant Funds Research for CART38, a Novel Therapy for T-ALL
In this Q&A, Drs. Teachey and Diorio discuss their partnership and research of a novel CAR T-cell therapy for one of the most common pediatric cancers.

In The News: MIS-C, Antibody Treatment for Eosinophilic Esophagitis, ASH 2022

Published on
Jan 6, 2023
in Cornerstone Blog
Our Scientists’ Research Highlighted In the News
See highlights of work by Children’s Hospital of Philadelphia researchers that is leading to novel findings.

In the News: Outstanding Science Award, Highly Cited Researcher, STAT Wunderkinds

Published on
Dec 9, 2022
in Cornerstone Blog
In the News
This week's news roundup features an outstanding science award, Highly Cited Researchers, and STAT Wunderkinds, along with new research about cancer risk with birth defects, epilepsy, and acute myeloid leukemia.

In the News: Mitochondrial Disease, ALL, Type 2 Diabetes, Sleep Apnea

Published on
Sep 16, 2022
in Cornerstone Blog
In the News
This week’s In the News highlights research on mitochondrial disease, acute lymphoblastic leukemia, type 2 diabetes, and sleep apnea.

In the News: Autism and COVID, Telemedicine, Hemoglobin, Williams Syndrome, AYAs

Published on
Jun 10, 2022
in Cornerstone Blog
In the News
This week’s news roundup features discoveries related to COVID-19’s effect on adolescents, autism screening, telemedicine, and more.

In The News: Breastfeeding, Allogeneic CART, Costa Rica Partners, CPR Education, Cognitive Outcomes

Published on
May 27, 2022
in Cornerstone Blog
In the News
Learn about novel findings and notable achievements from our Children’s Hospital of Philadelphia researchers.

CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing

Published on
May 23, 2022
in Press Releases
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.

Snapshot Science: Does Bortezomib Improve Survival in Children With T-cell Lymphoblastic Leukemia?

Published on
Apr 4, 2022
in Cornerstone Blog
Does Bortezomib Improve Outcomes in T-cell Lymphoblastic Leukemia?
Researchers at CHOP found that bortezomib improve survival in children with T-cell lymphoblastic lymphoma.

New Ways Needed to Predict, Treat Relapsed Leukemia

Published on
Aug 4, 2015
in Cornerstone Blog
Despite advances in T-cell acute lymphoblastic leukemia treatment, between 15 and 20 percent of children who achieve an initial complete remission will relapse. They may need more intensive therapy or alternative approaches, but physicians do not yet have a reliable way of predicting which patients are at high-risk of relapse.

Daratumumab for T-cell ALL

Daratumumab for T-cell ALL

CHOP, in collaboration with Janssen Research & Development, is conducting a study for children and young adults up to 30 years old, with relapsed or refractory precursor T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. This clinical trial is adding the study drug, daratumumab, to a standard relapse chemotherapy regimen.

1 - 10 of 11